Stocks

Wall Street Analysts Recommend Progenity as a Strong Buy

The stock market has fluctuated during the last few weeks. After the big sell-off, the futures climbed up again. However, they are still far from big gains. Experts determined now is a good time to buy some stocks. But which ones will bring profit in the future? With the current uncertain situation, it’s not an easy question. Logically, the best choice is to buy the stock, which has great potential, but it trading low right now.

According to Wall Street analysts, Progenity is such a company. This firm provides testing services, and it offers clear and actionable genetic results. Piper Sandler analyst Steven Mah noted that even against Covid-19’s backdrop, Progenity delivered with its second-quarter performance this year.

The company’s shares tumbled down by 44% since June. However, it began trading on Nasdaq, which will bring the stock success with more time. Meanwhile, its shares are trading for $8.11, offering an excellent buying opportunity.  

Mah gave this stock a Buy rating and set his price target at $17. Investors could gain 105% over the year with this company. The analyst thinks that the stock is undervalued, considering the robust rebound in the core testing business. He advises grabbing its shares now.

Related Post

Why is this company poised to gain?

The firm’s records speak for its reproductive tests’ durability and the success that the Progenity has in co-marketing. It did not provide guidance for the last quarter, but June test volumes of ~28,000 were strong.

Despite the pandemic, the company managed to maintain its leading pre-COVID test turnaround times. Additionally, the fourth generation NIPT test could measure the fetal fraction. Progenity will continue its development in 2021.

Analysts are looking forward to completing the preeclampsia verification in the fourth quarter of 2020, along with a possible 2H21 launch. The technology could potentially be applied to epigenetic markers, RNA, DNA, and proteins for additional clinical applications such as oncology.

Recent Posts

Nio Launches L60 SUV at ¥219,900 Amid EV Turmoil

Key Points: Nio launched the Onvo brand: Introduced the L60 SUV, targeting the family car segment with smart Electric Vehicle…

8 hours ago

Bitcoin Surges 7.5% to $66,350 Amid Volatility

Key Points: Bitcoin's value has soared to $66,350, marking a 7.50% increase, supported by bullish "Bullish Engulfing Candles." US inflation…

8 hours ago

European Stocks: Stoxx 600 Rises, Utilities Lead

Key Points: European Stocks Up: The Stoxx 600 rose by 0.6%; utilities soared by 1.7%. Record Highs in US and…

8 hours ago

Gold Price Hits $2,388.10, Edges Up by 0.1%

Key Points: Market expert predicts a potential rise to $2,400 for gold, dependent on economic cues like Federal Reserve decisions.…

12 hours ago

EUR/USD Reaches 1.0900, Gains for Fourth Week

Key Points: EUR/USD Ascension: The currency pair approaches a crucial level of 1.0900, highlighting its fourth weekly gain and the…

12 hours ago

GBP/USD Adjusts to 1.2688 Amid Key Economic Update

Key Points: Fed speakers and reports awaited: Comments from Fed officials and upcoming economic reports could impact GBP/USD volatility. US…

12 hours ago

This website uses cookies.